BACKGROUND Thrombocytopenia 2,an autosomal dominant inherited disease characterized by moderate thrombocytopenia,predisposition to myeloid malignancies and normal platelet size and function,can be caused by 5’-untran...BACKGROUND Thrombocytopenia 2,an autosomal dominant inherited disease characterized by moderate thrombocytopenia,predisposition to myeloid malignancies and normal platelet size and function,can be caused by 5’-untranslated region(UTR)point mutations in ankyrin repeat domain containing 26(ANKRD26).Runt related transcription factor 1(RUNX1)and friend leukemia integration 1(FLI1)have been identified as negative regulators of ANKRD26.However,the positive regulators of ANKRD26 are still unknown.AIM To prove the positive regulatory effect of GATA binding protein 2(GATA2)on ANKRD26 transcription.METHODS Human induced pluripotent stem cells derived from bone marrow(hiPSC-BM)INTRODUCTION Ankyrin repeat domain containing protein 26(ANKRD26)acts as a regulator of adipogenesis and is involved in the regulation of feeding behavior[1-3].The ANKRD26 gene is located on chromosome 10 and shares regions of homology with the primate-specific gene family POTE.According to the Human Protein Atlas database,the ANKRD26 protein is localized to the Golgi apparatus and vesicles,and its expression can be detected in nearly all human tissues[4].Moreover,UniProt annotation revealed that ANKRD26 is localized in the centrosome and contains coiled-coil domains formed by spectrin helices and ankyrin repeats[5,6].The most common disease related to ANKRD26 is thrombocytopenia 2(THC2),which is a rare autosomal dominant inherited disease characterized by lifelong mild-to-moderate thrombocytopenia and mild bleeding[7-9].Caused by the variants in the 5’-untranslated region(UTR)of ANKRD26,THC2 is defined by a decrease in the number of platelets in circulating blood and results in increased bleeding and decreased clotting ability[8,10].Due to the point mutations that occur in the 5’-UTR of ANKRD26,its negative transcription factors(TFs),Runt related transcription factor 1(RUNX1)and friend leukemia integration 1(FLI1),lose their repression effect[11].The persistent expression of ANKRD26 increases the activity of the mitogen activated protein kinase and extracellular signal regulated kinase 1/2 signaling pathways,which are potentially involved in the regulation of thrombopoietin-dependent signaling and further impair proplatelet formation by megakaryocytes(MKs)[11].However,the positive regulators of ANKRD26,which might be associated with THC2 pathology,are still unknown.展开更多
This editorial summarizes the latest literature on the roles of neuronal PAS domain protein 2 and KN motif/ankyrin repeat domain 1 in type 2 diabetes(T2D).We highlight their involvement inβ-cell dysfunction,explore t...This editorial summarizes the latest literature on the roles of neuronal PAS domain protein 2 and KN motif/ankyrin repeat domain 1 in type 2 diabetes(T2D).We highlight their involvement inβ-cell dysfunction,explore their potential as therapeutic targets,and discuss the implications for new treatment strategies.We offer valuable insights into relevant gene regulation and cellular mechanisms relevant for the targeted management of T2D.展开更多
Cardiac ankyrin repeat protein （CARP） not only serves as an important component of muscle sarcomere in the cytoplasm, but also acts as a transcription co-factor in the nucleus. Previous studies have demonstrated tha...Cardiac ankyrin repeat protein （CARP） not only serves as an important component of muscle sarcomere in the cytoplasm, but also acts as a transcription co-factor in the nucleus. Previous studies have demonstrated that CARP is up-regulated in some cardiovascular disorders and muscle diseases; however, its role in these diseases remains controversial now. In this review, we will discuss the continued progress in the research related to CARP, including its discovery, structure, and the role it plays in cardiac development and heart diseases.展开更多
Background： The Notch-regulated ankyrin repeat protein （NRARP） is recently found to promote proliferation of breast cancer cells. The role of NRARP in carcinogenesis deserves extensive investigations. This study at...Background： The Notch-regulated ankyrin repeat protein （NRARP） is recently found to promote proliferation of breast cancer cells. The role of NRARP in carcinogenesis deserves extensive investigations. This study attempted to investigate the expression of NRARP in thyroid cancer tissues and assess the influence of NRARP on cell proliferation, apoptosis, cell cycle, and invasion in thyroid cancer. Methods： Thirty-four cases with thyroid cancer were collected from the Department of General Surgery, Xinhua Hospital, Shanghai ]iao Tong University School of Medicine between 2011 and 2012. lmmunohistochemistry was used to detect the level of N RARP in cancer tissues. Lentivirus carrying NRARP-shRNA （Lenti-NRARP-shRNA） was applied to down-regulate NRARP expression. Cell viability was tested after treatment with Lenti-NRARP-shRNA using 3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromide assay. Apoptosis and cell cycle distribution were determined by flow cytometry. Cell invasion was tested using Transwell invasion assay. In addition, expressions of several cell cycle-associated and apoptosis-associated proteins were examined using Western blotting after transfection. Student＇s t-test, one-way analysis of variance （ANOVA）, or Kaplan Meier were used to analyze the differences between two group or three groups. Results： N RARP was highly expressed in thyroid cancer tissues. Lenti-NRARP-shRNA showed significantly inhibitory activities against cell growth at a multiplicity of infection of l 0 or higher （P 〈 0.05）. Lenti-NRARP-shRNA-induced G 1 arrest （BHTl 01 ： 72.57% ± 5.32%; g305C： 75.45% ± 5.26%） by promoting p21 expression, induced apoptosis by promoting bax expression and suppressing bcl-2 expression, and inhibited cell invasion by suppressing matrix metalloproteinase-9 expression. Conclusion： Downregulation of NRARP expression exerts significant antitumor activities against cell growth and invasion of thyroid cancer, that suggests a potential role of NRARP in thyroid cancer targeted therapy.展开更多
目的探讨结直肠癌(colorectal cancer,CRC)组织ras反应元件结合蛋白1(ras-responsive element binding protein 1,RREB1),ankyrin重复结构域1(ankyrin repeat domain 1,ANKRD1)的表达及与临床病理特征和预后不良的关系。方法选取2013年1...目的探讨结直肠癌(colorectal cancer,CRC)组织ras反应元件结合蛋白1(ras-responsive element binding protein 1,RREB1),ankyrin重复结构域1(ankyrin repeat domain 1,ANKRD1)的表达及与临床病理特征和预后不良的关系。方法选取2013年1月~2016年12月复旦大学附属中山医院厦门医院收治的105例CRC患者,应用免疫组织化学SP法检测CRC患者癌组织和癌旁组织RREB1和ANKRD1蛋白表达,分析RREB1和ANKRD1蛋白表达与患者临床病理特征的关系,患者均随访5年,比较不同RREB1和ANKRD1表达患者的预后情况,并分析CRC患者预后不良的影响因素。采用Spearman相关系数分析RREB1与ANKRD1表达的相关性。结果CRC癌组织RREB1蛋白阳性率(59.05%)显著高于癌旁组织(27.61%),差异有统计学意义(χ^(2)=21.120,P=0.000)。CRC癌组织ANKRD1蛋白阳性率(31.43%)显著低于癌旁组织(60.95%),差异有统计学意义(χ^(2)=18.410,P=0.000)。TNM分期Ⅲ期、淋巴结转移N1~N2患者RREB1蛋白阳性率高于TNM分期Ⅰ~Ⅱ期、淋巴结转移N0患者,差异有统计学意义(χ^(2)=4.263,8.199,均P<0.05)。TNM分期Ⅲ期、淋巴结转移N1~N2患者ANKRD1蛋白阳性率低于TNM分期Ⅰ~Ⅱ期、淋巴结转移N0患者,差异有统计学意义(χ^(2)=5.515,7.411,均P<0.05)。RREB1高表达组5年生存率(54.84%)低于RREB1低表达组(74.42%),差异有统计学意义(χ^(2)=5.459,P=0.020);ANKRD1高表达组的5年生存率(78.79%)高于ANKRD1低表达组(55.56%),差异有统计学意义(χ^(2)=5.130,P=0.024)。RREB1高表达(HR=2.437,95%CI:1.113~4.684)、ANKRD1低表达(HR=0.573,95%CI:0.185~1.952)、TNM分期Ⅲ期(HR=2.202,95%CI:1.357~4.215)和淋巴结转移N1~N2(HR=1.247,95%CI:1.532~4.368)是CRC患者预后不良的危险因素(均P<0.05)。Spearman秩相关分析结果,CRC癌组织中RREB1与ANKRD1表达呈负相关(r=-0.389,P=0.036)。结论CRC癌组织中RREB1表达升高,而ANKRD1表达降低,二者共同参与CRC的发生发展,有望成为评估CRC患者预后的组织肿瘤标志物。展开更多
基金Supported by General Program of National Natural Science Foundation of China,No.81770197Scientific and Technological Research Major Program of Chongqing Municipal Education Commission,No.KJZD-M202312802+1 种基金Chongqing Natural Science Foundation of China,No.CSTB2022NSCQ-MSX0190,No.CSTB2022NSCQ-MSX0176,and No.cstc2020jcyj-msxmX0051Xinqiao Young Postdoc Talent Incubation Program,No.2022YQB098.
文摘BACKGROUND Thrombocytopenia 2,an autosomal dominant inherited disease characterized by moderate thrombocytopenia,predisposition to myeloid malignancies and normal platelet size and function,can be caused by 5’-untranslated region(UTR)point mutations in ankyrin repeat domain containing 26(ANKRD26).Runt related transcription factor 1(RUNX1)and friend leukemia integration 1(FLI1)have been identified as negative regulators of ANKRD26.However,the positive regulators of ANKRD26 are still unknown.AIM To prove the positive regulatory effect of GATA binding protein 2(GATA2)on ANKRD26 transcription.METHODS Human induced pluripotent stem cells derived from bone marrow(hiPSC-BM)INTRODUCTION Ankyrin repeat domain containing protein 26(ANKRD26)acts as a regulator of adipogenesis and is involved in the regulation of feeding behavior[1-3].The ANKRD26 gene is located on chromosome 10 and shares regions of homology with the primate-specific gene family POTE.According to the Human Protein Atlas database,the ANKRD26 protein is localized to the Golgi apparatus and vesicles,and its expression can be detected in nearly all human tissues[4].Moreover,UniProt annotation revealed that ANKRD26 is localized in the centrosome and contains coiled-coil domains formed by spectrin helices and ankyrin repeats[5,6].The most common disease related to ANKRD26 is thrombocytopenia 2(THC2),which is a rare autosomal dominant inherited disease characterized by lifelong mild-to-moderate thrombocytopenia and mild bleeding[7-9].Caused by the variants in the 5’-untranslated region(UTR)of ANKRD26,THC2 is defined by a decrease in the number of platelets in circulating blood and results in increased bleeding and decreased clotting ability[8,10].Due to the point mutations that occur in the 5’-UTR of ANKRD26,its negative transcription factors(TFs),Runt related transcription factor 1(RUNX1)and friend leukemia integration 1(FLI1),lose their repression effect[11].The persistent expression of ANKRD26 increases the activity of the mitogen activated protein kinase and extracellular signal regulated kinase 1/2 signaling pathways,which are potentially involved in the regulation of thrombopoietin-dependent signaling and further impair proplatelet formation by megakaryocytes(MKs)[11].However,the positive regulators of ANKRD26,which might be associated with THC2 pathology,are still unknown.
文摘This editorial summarizes the latest literature on the roles of neuronal PAS domain protein 2 and KN motif/ankyrin repeat domain 1 in type 2 diabetes(T2D).We highlight their involvement inβ-cell dysfunction,explore their potential as therapeutic targets,and discuss the implications for new treatment strategies.We offer valuable insights into relevant gene regulation and cellular mechanisms relevant for the targeted management of T2D.
基金Project supported by the National Natural Science Foundation of China(No.31171392)
文摘Cardiac ankyrin repeat protein （CARP） not only serves as an important component of muscle sarcomere in the cytoplasm, but also acts as a transcription co-factor in the nucleus. Previous studies have demonstrated that CARP is up-regulated in some cardiovascular disorders and muscle diseases; however, its role in these diseases remains controversial now. In this review, we will discuss the continued progress in the research related to CARP, including its discovery, structure, and the role it plays in cardiac development and heart diseases.
文摘Background： The Notch-regulated ankyrin repeat protein （NRARP） is recently found to promote proliferation of breast cancer cells. The role of NRARP in carcinogenesis deserves extensive investigations. This study attempted to investigate the expression of NRARP in thyroid cancer tissues and assess the influence of NRARP on cell proliferation, apoptosis, cell cycle, and invasion in thyroid cancer. Methods： Thirty-four cases with thyroid cancer were collected from the Department of General Surgery, Xinhua Hospital, Shanghai ]iao Tong University School of Medicine between 2011 and 2012. lmmunohistochemistry was used to detect the level of N RARP in cancer tissues. Lentivirus carrying NRARP-shRNA （Lenti-NRARP-shRNA） was applied to down-regulate NRARP expression. Cell viability was tested after treatment with Lenti-NRARP-shRNA using 3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromide assay. Apoptosis and cell cycle distribution were determined by flow cytometry. Cell invasion was tested using Transwell invasion assay. In addition, expressions of several cell cycle-associated and apoptosis-associated proteins were examined using Western blotting after transfection. Student＇s t-test, one-way analysis of variance （ANOVA）, or Kaplan Meier were used to analyze the differences between two group or three groups. Results： N RARP was highly expressed in thyroid cancer tissues. Lenti-NRARP-shRNA showed significantly inhibitory activities against cell growth at a multiplicity of infection of l 0 or higher （P 〈 0.05）. Lenti-NRARP-shRNA-induced G 1 arrest （BHTl 01 ： 72.57% ± 5.32%; g305C： 75.45% ± 5.26%） by promoting p21 expression, induced apoptosis by promoting bax expression and suppressing bcl-2 expression, and inhibited cell invasion by suppressing matrix metalloproteinase-9 expression. Conclusion： Downregulation of NRARP expression exerts significant antitumor activities against cell growth and invasion of thyroid cancer, that suggests a potential role of NRARP in thyroid cancer targeted therapy.
文摘目的探讨结直肠癌(colorectal cancer,CRC)组织ras反应元件结合蛋白1(ras-responsive element binding protein 1,RREB1),ankyrin重复结构域1(ankyrin repeat domain 1,ANKRD1)的表达及与临床病理特征和预后不良的关系。方法选取2013年1月~2016年12月复旦大学附属中山医院厦门医院收治的105例CRC患者,应用免疫组织化学SP法检测CRC患者癌组织和癌旁组织RREB1和ANKRD1蛋白表达,分析RREB1和ANKRD1蛋白表达与患者临床病理特征的关系,患者均随访5年,比较不同RREB1和ANKRD1表达患者的预后情况,并分析CRC患者预后不良的影响因素。采用Spearman相关系数分析RREB1与ANKRD1表达的相关性。结果CRC癌组织RREB1蛋白阳性率(59.05%)显著高于癌旁组织(27.61%),差异有统计学意义(χ^(2)=21.120,P=0.000)。CRC癌组织ANKRD1蛋白阳性率(31.43%)显著低于癌旁组织(60.95%),差异有统计学意义(χ^(2)=18.410,P=0.000)。TNM分期Ⅲ期、淋巴结转移N1~N2患者RREB1蛋白阳性率高于TNM分期Ⅰ~Ⅱ期、淋巴结转移N0患者,差异有统计学意义(χ^(2)=4.263,8.199,均P<0.05)。TNM分期Ⅲ期、淋巴结转移N1~N2患者ANKRD1蛋白阳性率低于TNM分期Ⅰ~Ⅱ期、淋巴结转移N0患者,差异有统计学意义(χ^(2)=5.515,7.411,均P<0.05)。RREB1高表达组5年生存率(54.84%)低于RREB1低表达组(74.42%),差异有统计学意义(χ^(2)=5.459,P=0.020);ANKRD1高表达组的5年生存率(78.79%)高于ANKRD1低表达组(55.56%),差异有统计学意义(χ^(2)=5.130,P=0.024)。RREB1高表达(HR=2.437,95%CI:1.113~4.684)、ANKRD1低表达(HR=0.573,95%CI:0.185~1.952)、TNM分期Ⅲ期(HR=2.202,95%CI:1.357~4.215)和淋巴结转移N1~N2(HR=1.247,95%CI:1.532~4.368)是CRC患者预后不良的危险因素(均P<0.05)。Spearman秩相关分析结果,CRC癌组织中RREB1与ANKRD1表达呈负相关(r=-0.389,P=0.036)。结论CRC癌组织中RREB1表达升高,而ANKRD1表达降低,二者共同参与CRC的发生发展,有望成为评估CRC患者预后的组织肿瘤标志物。
